Compare SAIC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIC | RNA |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.0B |
| IPO Year | N/A | 2020 |
| Metric | SAIC | RNA |
|---|---|---|
| Price | $114.73 | $72.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | ★ $119.44 | $69.26 |
| AVG Volume (30 Days) | 555.9K | ★ 2.1M |
| Earning Date | 12-04-2025 | 02-26-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 33.14 | N/A |
| EPS | ★ 7.83 | N/A |
| Revenue | ★ $7,350,000,000.00 | $20,868,000.00 |
| Revenue This Year | N/A | $57.30 |
| Revenue Next Year | $1.75 | $28.41 |
| P/E Ratio | $14.56 | ★ N/A |
| Revenue Growth | N/A | ★ 106.27 |
| 52 Week Low | $84.16 | $21.51 |
| 52 Week High | $124.11 | $72.61 |
| Indicator | SAIC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 75.22 | 72.34 |
| Support Level | $100.00 | $72.04 |
| Resistance Level | $103.58 | $72.47 |
| Average True Range (ATR) | 2.85 | 0.18 |
| MACD | 0.97 | -0.20 |
| Stochastic Oscillator | 95.03 | 73.68 |
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the Department of Defence (DoD) and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.